Chief Commercial Officer · 10x Genomics, Inc. (TXG)

James Wilbur

FY2022 is the first fiscal year CompBrief holds for James Wilbur as a named executive officer of 10x Genomics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$8,892,052

Salary $171,282Stock awards $3,226,899Bonus $219,500

4th of 5 named executive officers at 10x Genomics by FY2022 total.

5 named officers on file for 10x Genomics, FY2022

James Wilbur’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • TXG’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how 10x Genomics’s whole pay program stands against its peers

  • 10x Genomics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TXG→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get James Wilbur’s full pay file as a PDF — free

More than this page: up to 10 years of James’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

James Wilbur compensation by year

10x Genomics Summary Compensation Table · the one fiscal year held
In US dollars, as 10x Genomics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$171,282
Bonus$219,500
Stock awards$3,226,899
Option awards$5,274,371
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$8,892,052

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 10x Genomics, Inc. DEF 14A filed April 28, 2023, accession 0001770787-23-000021, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 10x Genomics, Inc. filed document, accession 0001770787-23-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU95,839$3,492,373—
Option239,596—$33.67

Per the Outstanding Equity Awards at Fiscal Year-End table in 10x Genomics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

10x Genomics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Serge SaxonovChief Executive Officer$18,805,294
Eric WhitakerChief Legal Officer$11,903,680
Benjamin HindsonPresident and Chief Scientific Officer$9,869,889
James Wilbur · this pageChief Commercial Officer$8,892,052
Justin McAnearChief Financial Officer$6,842,330

The full 10x Genomics compensation record

free company brief

This page is one person within 10x Genomics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the 10x Genomics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 10x Genomics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Wilbur's compensation dossier · One-time report. No refunds.